Alector Inc
Alector Inc (NASDAQ: ALEC) is a clinical-stage biopharmaceutical company focused on immuno‑neurology, developing therapies that modulate the immune system to treat neurodegenerative diseases such as Alzheimer’s and ALS. With a market capitalisation of about $324.89M, it sits in the small‑cap, high‑risk segment where valuation is often driven by trial results and regulatory milestones rather than steady revenues. Investors should be aware that Alector’s value is closely tied to the progress of its pipeline, partnering agreements and its ability to raise further capital. Clinical outcomes can be binary and may produce sharp share price moves. Key factors to watch include upcoming data readouts, cash runway, collaboration deals and regulatory interactions. This is general educational information and not personalised investment advice — biotech investing carries significant risk and investors should consider suitability, diversification and time horizon before exposure.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Alector's stock with a target price of $2.20, indicating moderate growth potential.
Financial Health
Alector Inc has moderate revenue and cash flow, but its book value per share is low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ALEC
Early Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: October 14, 2025
Explore BasketBeyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketThe Alzheimer's Treatment Ecosystem
Following the EU regulator's approval of Eli Lilly's Alzheimer's drug, Kisunla, a new investment opportunity has emerged. This theme focuses on companies that provide essential support services, such as genetic testing and advanced imaging, which are crucial for the drug's administration and monitoring.
Published: July 27, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical data readouts and regulatory milestones can move the share price significantly; outcomes are binary and uncertain, so monitor timelines closely.
Scientific Approach
Alector targets innate immune pathways in neurodegeneration, an emerging scientific area with potential upside but considerable biological and execution risk.
Capital & Partnerships
As a small‑cap developer, Alector may rely on partnerships or financing to fund operations; such moves can de‑risk programmes but may dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
